In 271 adults with active lupus nephritis on mycophenolate and prednisone, obinutuzumab gave more complete renal responses at week 76 than placebo (46.4% vs 33.1%; difference 13.4 points), with more serious adverse events, mainly infections and COVID-19.
RCTn = 271
Furie et al. Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis